Granisetron Kabi

Granisetron Kabi is a prescription medication that contains the active ingredient granisetron hydrochloride. It is supplied in an intravenous formulation, with strength not specified in the available data. Classified as a 5‑HT3 receptor antagonist, Granisetron Kabi belongs to the antiemetic therapeutic class and is marketed in the European Union. It works by selectively blocking serotonin receptors to help prevent nausea and vomiting in patients undergoing chemotherapy or surgery.

Granisetron Kabi is indicated for the prevention of nausea and vomiting associated with specific medical procedures and treatments.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated. - Administration in settings where rapid onset of antiemetic effect is required, such as during anesthesia induction. - Management of nausea and vomiting related to radiotherapy when combined with other antiemetics. - Use in patients who have experienced inadequate control of nausea with other 5‑HT3 antagonists.

The safety profile of Granisetron Kabi includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common: - Headache, often mild and transient. - Constipation, may require dietary adjustment. - Diarrhea, usually self‑limiting. - Fatigue, generally resolves with continued therapy. - Dizziness, typically mild. - Dry mouth, occasional. - Flushing, brief episodes.

Serious: - Allergic reactions such as rash, pruritus, or angioedema, requiring immediate medical attention. - Cardiac arrhythmias, including QT interval prolongation, which may necessitate ECG monitoring. - Severe hypotension, potentially leading to syncope. - Rare cases of serotonin syndrome when combined with serotonergic agents.

When prescribing Granisetron Kabi, clinicians should consider several precautionary measures to ensure safe use and to identify patients who may be at increased risk of adverse outcomes.

- Assess patient history for cardiac conduction disorders before initiating therapy. - Use caution in patients with electrolyte imbalances that may predispose to QT prolongation. - Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Monitor renal and hepatic function in patients with severe impairment, adjusting therapy as needed. - Avoid use with other medications that significantly prolong the QT interval.

Granisetron Kabi may interact with other drugs, influencing its efficacy or safety; awareness of these interactions helps guide clinical decisions.

Avoid: - Other potent QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). - Concurrent use with other 5‑HT3 receptor antagonists, which can increase risk of additive side effects.

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, or tramadol, due to potential serotonin syndrome. - Drugs metabolized by CYP3A4, as granisetron is partially cleared via this pathway (e.g., certain antifungals, calcium channel blockers). - Medications that affect electrolyte balance (e.g., diuretics) which may exacerbate QT prolongation.